Mergers & Acquisitions ·
NextCure reports Q3 net loss of $6.8M as merger financing rises to $820M
NXTCNextCure, Inc.
NextCure reported a third-quarter 2026 net loss of $6.8 million, an improvement from the $8.6 million loss in the prior-year period, driven by lower research and development expenses and restructuring gains. Cash reserves declined to $8.7 million as the company funded operations and legal fees related to its proposed merger with Avere Therapeutics. The transaction's committed financing increased to approximately $820 million, supported by a syndicate of investors. The SEC declared the S-4 registration statement effective on November 6, 2026, and NextCure has scheduled a stockholder vote for December 9, 2026. NextCure is a biopharmaceutical company focused on advancing its merger with Avere Therapeutics while managing legacy assets.